Total Payments
$79,815
2024 Payments
$2,609
Companies
20
Transactions
64
Medicare Patients
1,361
Medicare Billing
$116,731
Payment Breakdown by Category
Consulting$73,143 (91.6%)
Research$3,595 (4.5%)
Other$2,500 (3.1%)
Food & Beverage$543.22 (0.7%)
Education$34.22 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $73,143 | 42 | 91.6% |
| Unspecified | $3,595 | 1 | 4.5% |
| Honoraria | $2,500 | 5 | 3.1% |
| Food and Beverage | $543.22 | 13 | 0.7% |
| Education | $34.22 | 3 | 0.0% |
Payments by Type
General
$76,220
63 transactions
Research
$3,595
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32,650 | 30 | $0 (2024) |
| PFIZER INC. | $18,785 | 5 | $0 (2023) |
| F. Hoffmann-La Roche AG | $9,300 | 3 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $8,761 | 4 | $0 (2023) |
| Roche Products Limited | $3,000 | 1 | $0 (2020) |
| Athenex Pharmaceutical Division, LLC | $2,500 | 5 | $0 (2020) |
| Eisai Co., Ltd. | $1,875 | 1 | $0 (2020) |
| Clovis Oncology, Inc. | $1,500 | 1 | $0 (2017) |
| Halozyme Inc | $900.00 | 1 | $0 (2019) |
| G1 Therapeutics, Inc. | $182.41 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,609 | 4 | Merck Sharp & Dohme LLC ($2,500) |
| 2023 | $7,439 | 6 | PFIZER INC. ($3,595) |
| 2022 | $10,714 | 6 | AstraZeneca Pharmaceuticals LP ($7,656) |
| 2021 | $12,312 | 7 | F. Hoffmann-La Roche AG ($6,300) |
| 2020 | $14,275 | 12 | Merck Sharp & Dohme Corporation ($3,900) |
| 2019 | $3,990 | 8 | Merck Sharp & Dohme Corporation ($2,925) |
| 2018 | $6,860 | 9 | Merck Sharp & Dohme Corporation ($6,825) |
| 2017 | $21,616 | 12 | PFIZER INC. ($15,168) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 01/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $108.79 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2023 | PFIZER INC. | IBRANCE (Drug) | — | Cash or cash equivalent | $3,594.80 | Research |
| Study: PALBOCICLIB AFTER CDK AND ENDOCRINE THERAPY PACEA RANDOMIZED PHASE II STUDY OF FULVESTRANT PALBOCICLIB AND AVELUMAB FOR ENDOCRINE PRETREATED ERHER2 METASTATIC BREAST CANCER • Category: ONCOLOGY | ||||||
| 08/01/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 04/06/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $1,093.75 | General |
| Category: Oncology | ||||||
| 02/08/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 08/11/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Oncology | ||||||
| 07/28/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $3,906.25 | General |
| Category: Oncology | ||||||
| 07/27/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2022 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $182.41 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/21/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 05/12/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
| 04/02/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: BioOncology | ||||||
| 01/29/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: BioOncology | ||||||
| 01/06/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: ONCOLOGY | ||||||
| 12/28/2020 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 10/11/2020 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALBOCICLIB AFTER CDK AND ENDOCRINE THERAPY PACEA RANDOMIZED PHASE II STUDY OF FULVESTRANT PALBOCICLIB AND AVELUMAB FOR ENDOCRINE PRETREATED ERHER2 METASTATIC BREAST CANCER | PFIZER INC. | $3,595 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 299 | 439 | $81,665 | $23,594 |
| 2022 | 3 | 296 | 467 | $87,036 | $25,769 |
| 2021 | 4 | 365 | 599 | $117,371 | $36,843 |
| 2020 | 8 | 401 | 616 | $122,078 | $30,525 |
Total Patients
1,361
Total Services
2,121
Medicare Billing
$116,731
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 90 | 190 | $41,040 | $13,050 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 198 | 236 | $36,816 | $9,157 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 13 | $3,809 | $1,387 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 81 | 205 | $44,280 | $14,359 | 32.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 203 | 250 | $39,000 | $10,318 | 26.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $3,756 | $1,092 | 29.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 102 | 276 | $59,616 | $19,562 | 32.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 221 | 272 | $42,432 | $12,065 | 28.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 23 | 32 | $9,376 | $3,353 | 35.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 19 | 19 | $5,947 | $1,862 | 31.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 109 | 263 | $56,808 | $14,957 | 26.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 197 | 242 | $37,752 | $8,099 | 21.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 25 | 38 | $11,134 | $2,948 | 26.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 17 | 17 | $6,902 | $2,069 | 30.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 16 | 16 | $5,008 | $1,415 | 28.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 11 | 11 | $2,387 | $637.72 | 26.7% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 14 | 14 | $1,487 | $275.30 | 18.5% |
| 99446 | Telephone or internet assessment and management service provided byconsultative physician with verbal and written report, 5-10 minutes of medical consultative discussion and review | Facility | 2020 | 12 | 15 | $600.00 | $124.45 | 20.7% |
About Dr. Kathy Miller, MD
Dr. Kathy Miller, MD is a Hematology & Oncology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649236043.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kathy Miller, MD has received a total of $79,815 in payments from pharmaceutical and medical device companies, with $2,609 received in 2024. These payments were reported across 64 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($73,143).
As a Medicare-enrolled provider, Miller has provided services to 1,361 Medicare beneficiaries, totaling 2,121 services with total Medicare billing of $116,731. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Indianapolis, IN
- Active Since 04/25/2006
- Last Updated 03/14/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1649236043
Products in Payments
- KEYTRUDA (Biological) $31,400
- XTANDI (Drug) $15,168
- TECENTRIQ (Biological) $12,300
- ENHERTU (Biological) $8,750
- IBRANCE (Drug) $3,617
- Oral Paclitaxel (Drug) $2,500
- Halaven (Drug) $1,875
- Rubraca (Drug) $1,500
- COSELA (Drug) $182.41
- Enhertu (Drug) $108.79
- Auvi-Q (Drug) $27.18
- Venclexta (Drug) $24.99
- Verdeso (Drug) $16.29
- Otezla (Drug) $15.44
- AFINITOR (Drug) $12.46
- LYNPARZA (Drug) $10.97
- Imbruvica (Drug) $10.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Indianapolis
Mr. Ruemu Birhiray, Md, MD
Hematology & Oncology — Payments: $3.3M
Hematology & Oncology $3.3M
Dr. Richard Gaynor, M.d, M.D
Hematology & Oncology — Payments: $3.2M
Hematology & Oncology $3.2M
Dr. Michael Dugan, M.d, M.D
Hematology & Oncology — Payments: $320,093
Hematology & Oncology $320,093
Anand Tandra, M.d, M.D
Hematology & Oncology — Payments: $257,904
Hematology & Oncology $257,904
Dr. John Edwards, Md, MD
Hematology & Oncology — Payments: $193,104
Hematology & Oncology $193,104
Dr. Brandon Hardesty, M.d, M.D
Hematology & Oncology — Payments: $98,240
Hematology & Oncology $98,240